PMS3 LORECEVIVINT, A POTENTIAL DISEASE-MODIFYING TREATMENT FOR KNEE OSTEOARTHRITIS: FACTORS DRIVING WOMAC PAIN SUBSCORE CHANGES - A POST HOC ANALYSIS OF PHASE 2B DATA

Abstract

Knee osteoarthritis (OA) is a heterogenous disease characterized by pain, functional loss, and deformity, which can confound patient-reported outcomes (PROs). The WOMAC Pain subscore addresses this variability by capturing ‘active’ (A1–A2) and ‘static’ (A3–A5) pain items. We hypothesize that measurement of ‘active’ versus ‘static’ pain dimensions may demonstrate differential effect sizes (ES) when assessing treatment benefit. Lorecivivint (LOR; SM04690), a small-molecule, intra-articular CLK/DYRK1A inhibitor, is in development as a potential disease-modifying treatment for knee OA.